Literature DB >> 34008707

BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 2): UPDATE ON TREATMENT.

Leandro Cardoso Barchi1,2, Marcus Fernando Kodama Pertille Ramos1, André Roncon Dias1, Nora Manoukian Forones3, Marineide Prudêncio de Carvalho3, Osvaldo Antonio Prado Castro3, Paulo Kassab3, Wilson Luiz da Costa-Júnior4,5, Antônio Carlos Weston6, Bruno Zilberstein1,2, Álvaro Antônio Bandeira Ferraz, Amir ZeideCharruf, André Brandalise, André Maciel da Silva, Barlon Alves, Carlos Augusto Martinez Marins, Carlos Alberto Malheiros, Celso Vieira Leite, Claudio José Caldas Bresciani, Daniel Szor, Donato Roberto Mucerino, Durval R Wohnrath, Elias JirjossIlias, Euclides Dias Martins Filho, Fabio PinatelLopasso, Felipe José Fernandez Coimbra, Fernando E Cruz Felippe, Flávio Daniel Saavedra Tomasisch, Flavio Roberto Takeda, Geraldo Ishak, Gustavo Andreazza Laporte, Herbeth José Toledo Silva, Ivan Cecconello, Joaquim José Gama Rodrigues, José Carlos Del Grande, Laércio Gomes Lourenço, Leonardo Milhomem da Motta, Leonardo Rocha Ferraz, Luis Fernando Moreira, Luis Roberto Lopes, Marcelo Garcia Toneto, Marcelo Mester, Marco Antônio Gonçalves Rodrigues, Maurice Youssef Franciss, Nelson AdamiAndreollo, Oly Campos Corletta, Osmar Kenji Yagi, Osvaldo Malafaia, Paulo Pimentel Assumpção, Paulo Roberto Savassi-Rocha, Ramiro Colleoni Neto, Rodrigo Jose de Oliveira, Rubens Antonio AissarSallun, Rui Weschenfelder, Saint Clair Vieira de Oliveira, Thiago Boechat de Abreu, Tiago Biachi de Castria, Ulysses Ribeiro Junior, Williams Barra, Wilson Rodrigues de Freitas Júnior.   

Abstract

BACKGROUND: : The II Brazilian Consensus on Gastric Cancer of the Brazilian Gastric Cancer Association BGCA (Part 1) was recently published. On this occasion, countless specialists working in the treatment of this disease expressed their opinion in the face of the statements presented. AIM: : To present the BGCA Guidelines (Part 2) regarding indications for surgical treatment, operative techniques, extension of resection and multimodal treatment.
METHODS: To formulate these guidelines, the authors carried out an extensive and current review regarding each declaration present in the II Consensus, using the Medline/PubMed, Cochrane Library and SciELO databases initially with the following descriptors: gastric cancer, gastrectomy, lymphadenectomy, multimodal treatment. In addition, each statement was classified according to the level of evidence and degree of recommendation.
RESULTS: : Of the 43 statements present in this study, 11 (25,6%) were classified with level of evidence A, 20 (46,5%) B and 12 (27,9%) C. Regarding the degree of recommendation, 18 (41,9%) statements obtained grade of recommendation 1, 14 (32,6%) 2a, 10 (23,3%) 2b e one (2,3%) 3.
CONCLUSION: : The guidelines complement of the guidelines presented here allows surgeons and oncologists who work to combat gastric cancer to offer the best possible treatment, according to the local conditions available.

Entities:  

Mesh:

Year:  2021        PMID: 34008707     DOI: 10.1590/0102-672020210001e1563

Source DB:  PubMed          Journal:  Arq Bras Cir Dig        ISSN: 0102-6720


  3 in total

1.  ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS.

Authors:  Juliana Silveira Lima de Castro; Adriane Graicer Pelosof; João Guilherme Guerra de Andrade-Cabral; Alvaro Moura Seraphim; Eloy Taglieri; Felipe Jose Fernandez Coimbra; Claudia Zitron
Journal:  Arq Bras Cir Dig       Date:  2022-01-05

2.  SURGICAL TREATMENT IN CLINICAL STAGE IV GASTRIC CANCER: A COMPARISON OF DIFFERENT PROCEDURES AND SURVIVAL OUTCOMES.

Authors:  Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; André Roncon Dias; Tiago Biachi de Castria; Erica Sakamoto; Ulysses Ribeiro-Jr; Bruno Zilberstein; Sérgio Carlos Nahas
Journal:  Arq Bras Cir Dig       Date:  2022-06-17

3.  Impact of COVID-19 pandemic on the surgical treatment of gastric cancer.

Authors:  Amanda Juliani Arneiro; Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; André Roncon Dias; Bruno Zilberstein; Ulysses Ribeiro Junior; Sergio Carlos Nahas
Journal:  Clinics (Sao Paulo)       Date:  2021-11-26       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.